3-甲基-1-(甲苯-4-磺酰基)哌嗪 | 178624-90-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-甲基-1-(甲苯-4-磺酰基)哌嗪
• 英文名称: (3S)-3-methyl-1-[(4-methylbenzene)sulfonyl]piperazine
• 英文别名: 3-Methyl-1-(toluene-4-sulfonyl)-piperazine；3-methyl-1-(4-methylphenyl)sulfonylpiperazine
• CAS: 178624-90-3
• 化学式: C₁₂H₁₈N₂O₂S
• 分子量: 254.353
• InChiKey: KVFXTJXVCJULLQ-UHFFFAOYSA-N

物化性质

• 沸点：
  391.2±52.0 °C(Predicted)
• 密度：
  1.171±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  57.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  3-甲基-1-(甲苯-4-磺酰基)哌嗪 在 盐酸 、 sodium tetrahydroborate 、 potassium carbonate 、 potassium iodide 作用下， 以 乙醇 、 乙腈 为溶剂， 反应 50.0h， 生成 1-(4-Fluorophenyl)-4-[2-methyl-4-(4-methylphenyl)sulfonylpiperazin-1-yl]butan-1-ol
  参考文献：
  名称：

  7-[3-(1-Piperidinyl)propoxy]chromenones as Potential Atypical Antipsychotics

  摘要：

  Compound 1 (1-benzyl-3-methyl-4-[4-(4-fluorophenyl)- a synthetic intermediate identified as a potential atypical antipsychotic, was selected as the starting point for pharmacological improvement. From 1, sequential structural variations were conducted in order to improve its potency and oral bioavailability. These variations included a series of piperazine, ethanediamine, and piperidine derivatives. The piperidine series afforded some orally potent compounds in the inhibition of apomorphine-induced climbing and hyperactivity in mice, which are regarded as behavioral models predictive of antipsychotic efficacy. Further optimization of these structures led to the highly potent 7-[3-(1-piperidinyl)propoxy]chromenones. Inhibition of stereotypies and induction of catalepsy in rats at doses substantially higher than required for inhibition of climbing suggest an atypical antipsychotic profile, which is assumed to predict a reduced induction of extrapyramidal side effects in humans.

  DOI：

  10.1021/jm950894b
• 作为产物：
  描述：

  [[2-(methoxyimino)propyl][(4-methylphenyl)sulfonyl]amino]acetaldehyde 在 偶氮二异丁腈 、 三正丁基氢锡 、 红铝 作用下， 以 正己烷 、 甲苯 、 苯 为溶剂， 反应 5.0h， 生成 3-甲基-1-(甲苯-4-磺酰基)哌嗪
  参考文献：
  名称：

  杂环合成中的自由基环化。第9部分：1通过糖类衍生的肟醚的Stannyl自由基环化反应合成氨基环醇和相关化合物2

  摘要：

  斯坦尼基自由基加成反应-衍生自d-葡萄糖，d-半乳糖和d-木糖的肟醚的环化反应顺利进行，得到的烷氧基氨基醇可有效地转变为两种类型的糖苷酶抑制剂或其候选物，例如氨基环糖醇，1-脱氧野oji霉素和1-脱氧半乳糖抑素通过反式烷氧基氨基醇的还原性扩环而形成。

  DOI：

  10.1016/s0040-4020(00)00545-7

文献信息

• Tertiary amine-promoted enone aziridination: investigations into factors influencing enantioselective induction
  作者：Alan Armstrong、Robert D.C. Pullin、Chloe R. Jenner、Klement Foo、Andrew J.P. White、James N. Scutt

  DOI：10.1016/j.tetasy.2013.11.008

  日期：2014.1

  synthesised (up to 77% ee) via a chiral tertiary amine-promoted nucleophilic aziridination of α,β-unsaturated ketones utilising in situ generated N–N ylides (aminimines). A wide range of chiral tertiary amines were synthesised and evaluated, allowing structure–activity relationships to be drawn. The most efficient promoter for asymmetric aziridination, quinine, was assessed with several enones to ascertain

  通过手性叔胺促进的α，β-不饱和酮的手性叔胺促进的亲核叠氮反应，利用原位生成的N - N酰基化物（氨基胺）合成了反式N-未取代的氮丙啶（至多77％ee ）。合成并评估了多种手性叔胺，从而可以得出结构-活性关系。用几种烯酮评估了不对称叠氮化的最有效启动子奎宁，以确定底物结构对产物ee的影响，而中间肼盐则通过X射线晶体学表征。
• Radical Cyclization in Heterocycle Synthesis. Part 9: A Novel Synthesis of Aminocyclitols and Related Compounds via Stannyl Radical Cyclization of Oxime Ethers Derived from Sugars
  作者：Toshiko Kiguchi、Kazumi Tajiri、Ichiya Ninomiya、Takeaki Naito

  DOI：10.1016/s0040-4020(00)00545-7

  日期：2000.8

  Stannyl radical addition–cyclization of oxime ethers derived from d-glucose, d-galactose, and d-xylose proceeded smoothly to afford alkoxyamino alcohols which were effectively converted into two types of glycosidase inhibitors or its candidates such as aminocyclitols, 1-deoxynojirimycin, and 1-deoxygalactostatin via reductive ring-expansion of trans alkoxyamino alcohols.

  斯坦尼基自由基加成反应-衍生自d-葡萄糖，d-半乳糖和d-木糖的肟醚的环化反应顺利进行，得到的烷氧基氨基醇可有效地转变为两种类型的糖苷酶抑制剂或其候选物，例如氨基环糖醇，1-脱氧野oji霉素和1-脱氧半乳糖抑素通过反式烷氧基氨基醇的还原性扩环而形成。
• 7-[3-(1-Piperidinyl)propoxy]chromenones as Potential Atypical Antipsychotics
  作者：Jordi Bolós、Santiago Gubert、Lluís Anglada、Josep M. Planas、Carme Burgarolas、Josep M. Castelló、Aurelio Sacristán、José A. Ortiz

  DOI：10.1021/jm950894b

  日期：1996.1.1

  Compound 1 (1-benzyl-3-methyl-4-[4-(4-fluorophenyl)- a synthetic intermediate identified as a potential atypical antipsychotic, was selected as the starting point for pharmacological improvement. From 1, sequential structural variations were conducted in order to improve its potency and oral bioavailability. These variations included a series of piperazine, ethanediamine, and piperidine derivatives. The piperidine series afforded some orally potent compounds in the inhibition of apomorphine-induced climbing and hyperactivity in mice, which are regarded as behavioral models predictive of antipsychotic efficacy. Further optimization of these structures led to the highly potent 7-[3-(1-piperidinyl)propoxy]chromenones. Inhibition of stereotypies and induction of catalepsy in rats at doses substantially higher than required for inhibition of climbing suggest an atypical antipsychotic profile, which is assumed to predict a reduced induction of extrapyramidal side effects in humans.